• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

羟氯喹和阿奇霉素治疗妊娠期 COVID-19：病例报告。

Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report.

机构信息

Department of Obstetrics and Gynecology, New York Health and Hospitals/Lincoln, Bronx, NY USA.

Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.

出版信息

Acta Biomed. 2020 Jul 16;91(4):e2020123. doi: 10.23750/abm.v91i4.10216.

DOI:10.23750/abm.v91i4.10216
PMID:33525254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927503/
Abstract

The combination of hydroxychloroquine (HCQ) and azithromycin could represent a suitable treatment for SarS-CoV-2 positive pregnancies. The authors report one of the first cases of COVID-19 positive pregnant woman successfully treated with HCQ in April 2020.

摘要

羟氯喹（HCQ）与阿奇霉素联合应用可能是治疗 SARS-CoV-2 阳性妊娠的一种合适方法。作者报告了首例成功应用 HCQ 治疗 COVID-19 阳性孕妇的病例，该患者于 2020 年 4 月接受治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/156b/7927503/8de32cf5308e/ACTA-91-123-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/156b/7927503/2564be8e7fb4/ACTA-91-123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/156b/7927503/8de32cf5308e/ACTA-91-123-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/156b/7927503/2564be8e7fb4/ACTA-91-123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/156b/7927503/8de32cf5308e/ACTA-91-123-g002.jpg

相似文献

1
Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report.羟氯喹和阿奇霉素治疗妊娠期 COVID-19：病例报告。
Acta Biomed. 2020 Jul 16;91(4):e2020123. doi: 10.23750/abm.v91i4.10216.
2
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.药物流行病学、机器学习和 COVID-19：羟氯喹（无论是否联合阿奇霉素）治疗意向分析，及其对住院美国退伍军人 COVID-19 结局的影响。
Am J Epidemiol. 2021 Nov 2;190(11):2405-2419. doi: 10.1093/aje/kwab183.
3
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?羟氯喹和阿奇霉素用于治疗新冠肺炎患者：是益友还是劲敌？
J Clin Pharmacol. 2020 Jul;60(7):808-814. doi: 10.1002/jcph.1646. Epub 2020 May 20.
4
Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.羟氯喹/阿奇霉素治疗 COVID-19 住院患者的 QT 间期和室性心律失常。
Int J Clin Pract. 2021 Feb;75(2):e13896. doi: 10.1111/ijcp.13896. Epub 2020 Dec 15.
5
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.羟氯喹和阿奇霉素对住院治疗的 COVID-19 肺炎患者无效：一项回顾性研究。
PLoS One. 2021 Jun 9;16(6):e0252388. doi: 10.1371/journal.pone.0252388. eCollection 2021.
6
Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.因 COVID-19 住院的患者接受非适应证羟氯喹和阿奇霉素治疗的临床结局和不良事件。
Br J Clin Pharmacol. 2021 Mar;87(3):1150-1154. doi: 10.1111/bcp.14482. Epub 2020 Aug 2.
7
Clinical improvement of severe COVID-19 pneumonia in a pregnant patient after caesarean delivery.剖宫产术后一名重症 COVID-19 肺炎孕妇的临床改善情况。
BMJ Case Rep. 2020 Jul 16;13(7):e236290. doi: 10.1136/bcr-2020-236290.
8
Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients.羟氯喹和阿奇霉素早期联合治疗可降低 10429 例 COVID-19 门诊患者的死亡率。
Rev Cardiovasc Med. 2021 Sep 24;22(3):1063-1072. doi: 10.31083/j.rcm2203116.
9
Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.羟氯喹预防 SARS-CoV-2 感染和妊娠期 COVID-19 疾病严重程度的疗效和安全性（COVID-Preg）：一项随机安慰剂对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):607. doi: 10.1186/s13063-020-04557-y.
10
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.

引用本文的文献

1
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.COVID-19治疗潜在药物和疫苗的临床前与临床研究：近期更新的综合综述
Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. eCollection 2024 Jan-Dec.
2
COVID-19 and Pregnancy.新冠病毒与妊娠
Discoveries (Craiova). 2022 Jun 30;10(2):e147. doi: 10.15190/d.2022.6. eCollection 2022 Apr-Jun.
3
An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.

本文引用的文献

1
Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.氯喹和羟氯喹在治疗伴有或不伴有糖尿病的2019冠状病毒病中的应用：一项系统检索及叙述性综述，特别提及印度和其他发展中国家
Diabetes Metab Syndr. 2020 May-Jun;14(3):241-246. doi: 10.1016/j.dsx.2020.03.011. Epub 2020 Mar 26.
2
Covid-19: how a virus is turning the world upside down.新冠疫情：一种病毒如何让世界天翻地覆。
BMJ. 2020 Apr 3;369:m1336. doi: 10.1136/bmj.m1336.
3
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).
观察性、回顾性、全面的羟氯喹相关心血管不良事件的药物警戒分析，纳入 COVID-19 患者和非 COVID-19 患者。
Int J Clin Pharm. 2022 Oct;44(5):1179-1187. doi: 10.1007/s11096-022-01457-w. Epub 2022 Jul 20.
4
Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.血心屏障渗漏机制：对 COVID-19 引起的心血管损伤的影响。
Int J Mol Sci. 2021 Dec 17;22(24):13546. doi: 10.3390/ijms222413546.
5
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?抗2019冠状病毒病病毒疗法的最新进展：我们取得了多大的进展？
Front Pharmacol. 2021 Mar 8;12:632677. doi: 10.3389/fphar.2021.632677. eCollection 2021.
拯救脓毒症运动：2019 冠状病毒病（COVID-19）危重症成人管理指南。
Intensive Care Med. 2020 May;46(5):854-887. doi: 10.1007/s00134-020-06022-5. Epub 2020 Mar 28.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5
COVID-19 and the liver: little cause for concern.新冠病毒与肝脏：无需过度担忧。
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):529-530. doi: 10.1016/S2468-1253(20)30084-4. Epub 2020 Mar 20.
6
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
7
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].《磷酸氯喹治疗新型冠状病毒肺炎专家共识》
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009.
8
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
9
[Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search].[风湿病学中抗疟药物治疗的安全管理。基于系统文献检索的跨学科建议]
Z Rheumatol. 2020 Mar;79(2):186-194. doi: 10.1007/s00393-020-00751-0.
10
[Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study].新型冠状病毒肺炎与肝功能损害关系的初步研究：一项多中心研究
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):107-111. doi: 10.3760/cma.j.issn.1007-3418.2020.02.003.